← Dashboard
Stock
UTHR
United Therapeutics CorporationHealth CareBiotechnologyLatest close $1.226 of 27 marquee funds currently hold15 CUSIPs mapped
Current holders
6
27 funds tracked
Ever held
17
Current + past
New this quarter
3
Exited this quarter
0
Marquee-fund ownership over time
Aug 14, 2013Nov 14, 2017May 15, 2023May 15, 2026
Now
18
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $330 | $1.22 | -100% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $39 | $1.22 | -97% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $1.22 | — |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $1.22 | — |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $1.22 | — |
| Point72 Asset Management re-entered | Q4 2024(8Q snapshot) | 6Q | $0.00 | $1.22 | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| AQR Capital Management 3× in & out | Q2 2025 | Q1 2026 | → $2.16 | +25% |
| Third Point 2× in & out | Q2 2025 | Q3 2025 | — | +0% |
| Maverick Capital 6× in & out | Q4 2024 | Q3 2025 | — | +0% |
| Duquesne Family Office 3× in & out | Q4 2024 | Q2 2025 | — | +0% |
| Bridgewater Associates 10× in & out | Q2 2024 | Q3 2024 | — | +0% |
| Coatue Management 2× in & out | Q1 2020 | Q2 2020 | — | +0% |
| JANA Partners | Q4 2018 | Q1 2019 | — | +0% |
| Viking Global Investors | Q2 2018 | Q4 2018 | — | +0% |
| Appaloosa | Q1 2017 | Q3 2017 | — | +0% |
| Greenlight Capital | Q4 2016 | Q1 2017 | — | +0% |
| Elliott Management 2× in & out | Q4 2014 | Q1 2015 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at UNITED THERAPEUTICS Corp. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
38
Filings · last 90d
106
Total on file
638
Recent SEC buffer
Most recent
Jun 9, 2026
30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.
- Form 40001636178-26-000025Jun 9, 2026
- Form 40001106578-26-000072Jun 9, 2026
- Form 40001106578-26-000071Jun 8, 2026
- Form 40001636178-26-000024Jun 5, 2026
- Form 40001106578-26-000070Jun 5, 2026
- Form 40001231589-26-000013Jun 4, 2026
- Form 40001106578-26-000069Jun 4, 2026
- Form 40001106578-26-000068Jun 3, 2026
- Form 40001106578-26-000067Jun 2, 2026
- Form 40001636178-26-000023Jun 2, 2026
- Form 4/Aamend0001106578-26-000066Jun 2, 2026
- Form 40001106578-26-000065Jun 1, 2026
- Form 40001636178-26-000022May 29, 2026
- Form 40001106578-26-000064May 29, 2026
- Form 40001106578-26-000063May 28, 2026
Showing 15 of 638 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · United Therapeutics CorporationAnnual figures sourced directly from United Therapeutics Corporation's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$3.18B
FY2025+11% YoY
Net income
$1.33B
FY2025+12% YoY
EPS (diluted)
$27.86
FY2025+13% YoY
Free cash flow(?)
$1.04B
FY2025-4% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for UNITED THERAPEUTICS Corp — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2026 | open | $55 | $55 | +0% |
| Citadel Advisors | Q2 2026 | open | $0.00 | — | +0% |
| Two Sigma Investments | Q2 2026 | open | $0.00 | — | +0% |
| Renaissance Technologies | Q2 2026 | open | $1.22 | $1.22 | +0% |
| Citadel Advisors | Q1 2026 | open | $32 | $58 | +81% |
| Citadel Advisors | Q1 2026 | open | $68 | $123 | +81% |
| Citadel Advisors | Q4 2025 | open | $79 | $102 | +29% |
| Point72 Asset Management | Q4 2025 | open | $466 | $567 | +22% |
| Citadel Advisors | Q3 2025 | Q4 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2025 | Q2 2026 | $0.00 | — | +0% |
| Renaissance Technologies | Q3 2025 | Q1 2026 | $4.20 | $2.40 | -43% |
| Citadel Advisors | Q2 2025 | open | $1.73 | $1.22 | -29% |
| Third Point | Q2 2025 | Q3 2025 | $0.00 | — | +0% |
| AQR Capital Management | Q2 2025 | Q1 2026 | $1.73 | $2.16 | +25% |
| Citadel Advisors | Q1 2025 | Q2 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q1 2025 | open | $371 | $567 | +53% |
| Citadel Advisors | Q4 2024 | Q1 2025 | $6.26 | $4.09 | -35% |
| Citadel Advisors | Q4 2024 | Q4 2025 | $0.00 | — | +0% |
| Maverick Capital | Q4 2024 | Q3 2025 | $0.00 | — | +0% |
| Duquesne Family Office | Q4 2024 | Q2 2025 | $0.00 | — | +0% |
| Point72 Asset Management | Q4 2024 | Q1 2025 | $0.00 | — | +0% |
| Renaissance Technologies | Q4 2024 | Q2 2025 | $6.37 | $1.76 | -72% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $39 | $36 | -6% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $60 | $72 | +20% |
| Citadel Advisors | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q4 2025 | $31 | $29 | -4% |
| Citadel Advisors | Q3 2024 | Q4 2025 | $64 | $69 | +9% |
| Citadel Advisors | Q3 2024 | Q2 2026 | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | Q1 2025 | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | open | $324 | $567 | +75% |
| D.E. Shaw | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | open | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | open | $324 | $567 | +75% |
| AQR Capital Management | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| AQR Capital Management | Q3 2024 | open | $324 | $567 | +75% |
| Millennium Management | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | open | $6.10 | $1.22 | -80% |
| Millennium Management | Q3 2024 | open | $324 | $567 | +75% |
| Renaissance Technologies | Q3 2024 | open | $330 | $567 | +72% |
| Bridgewater Associates | Q2 2024 | Q3 2024 | $0.00 | — | +0% |
| Third Point | Q4 2023 | Q2 2024 | $0.00 | — | +0% |
| Maverick Capital | Q2 2023 | Q4 2023 | $0.00 | — | +0% |
| Bridgewater Associates | Q3 2022 | open | $220 | $537 | +143% |
| Maverick Capital | Q2 2021 | Q1 2022 | $198 | $203 | +2% |
| Bridgewater Associates | Q3 2020 | Q1 2021 | $0.00 | — | +0% |
| Coatue Management | Q1 2020 | Q2 2020 | $0.00 | — | +0% |
| Bridgewater Associates | Q1 2020 | Q2 2020 | $0.00 | — | +0% |
| Maverick Capital | Q4 2019 | Q2 2020 | $90 | $116 | +30% |
| Bridgewater Associates | Q2 2019 | Q3 2019 | $91 | $80 | -11% |
| JANA Partners | Q4 2018 | Q1 2019 | $0.00 | — | +0% |
| Viking Global Investors | Q2 2018 | Q4 2018 | $0.00 | — | +0% |
| Maverick Capital | Q2 2018 | Q1 2019 | $0.00 | — | +0% |
| Duquesne Family Office | Q1 2018 | Q2 2018 | $0.00 | — | +0% |
| Bridgewater Associates | Q4 2017 | Q2 2019 | $0.00 | — | +0% |
| Bridgewater Associates | Q2 2017 | Q3 2017 | $0.00 | — | +0% |
| Appaloosa | Q1 2017 | Q3 2017 | $0.00 | — | +0% |
| Duquesne Family Office | Q1 2017 | Q2 2017 | $0.00 | — | +0% |
| Greenlight Capital | Q4 2016 | Q1 2017 | $0.00 | — | +0% |
| Coatue Management | Q2 2016 | Q3 2016 | $0.00 | — | +0% |
| Bridgewater Associates | Q1 2016 | Q1 2019 | $122 | $118 | -3% |
| Bridgewater Associates | Q3 2015 | Q1 2016 | $0.00 | — | +0% |
| Maverick Capital | Q2 2015 | Q4 2017 | $173 | $119 | -31% |
| Bridgewater Associates | Q1 2015 | Q2 2015 | $0.00 | — | +0% |
| Elliott Management | Q4 2014 | Q1 2015 | $0.00 | — | +0% |
| Elliott Management | Q3 2013 | Q2 2014 | $0.00 | — | +0% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.